R. Wolf

发表

Perceptions and Attitudes Toward the Use of Nebulized Therapy for COPD: Patient and Caregiver Perspectives

B. Make, A. Sharafkhaneh, S. Goodnight, 2013, COPD.

Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome

Lin Chang, G. Sayuk, R. Wolf, 2017, The American Journal of Gastroenterology.

EpiPen4Schools pilot survey: Occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting.

S. Silvia, M. White, S. Hogue, 2015, Allergy and asthma proceedings.

Epinephrine Administration for Cases of Anaphylaxis in a US School Setting: Results from the EpiPen4Schools Survey

S. Silvia, M. White, S. Hogue, 2015 .

Identifying factors associated with clinical success in patients treated with NASHA®/Dx injection for fecal incontinence

A. Barrett, R. Wolf, H. Franklin, 2016, Clinical and experimental gastroenterology.

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

P. Schoenfeld, A. Lembo, M. Pimentel, 2017, Digestive Diseases and Sciences.

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin

H. Dupont, M. Pimentel, R. Israel, 2016, Antimicrobial Agents and Chemotherapy.

Erratum to: Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

P. Schoenfeld, A. Lembo, M. Pimentel, 2017, Digestive Diseases and Sciences.

Regarding the use of epinephrine auto-injectors in remote settings.

R. Wolf, 2014, Wilderness & environmental medicine.